

1 Title: Additional Evidence Implicating GPD1L in the Pathogenesis of Brugada Syndrome in A Large Multi-  
2 generational Family

3  
4 Brief title: GPD1L Mutation and Brugada Syndrome

5  
6 Authors:

- 7 1. Greiner, Alexander M., B.A.<sup>a,b,c</sup>
- 8 2. Mehdi, Haider, Ph.D.<sup>a,b</sup>
- 9 3. Cevan, Chloe<sup>a</sup>
- 10 4. Gutmann, Rebecca, B.S.N.<sup>a</sup>
- 11 5. London, Barry, M.D., Ph.D.<sup>a,b,c</sup>

12  
13 Department and institutional affiliations:

14 A Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver  
15 College of Medicine, Iowa City, IA, United States of America

16 B Abboud Cardiovascular Research Center, University of Iowa Carver College of Medicine, Iowa City,  
17 IA, United States of America

18 C Interdisciplinary Graduate Program in Genetics, University of Iowa, Iowa City, IA, United States of  
19 America

20  
21 Funding: This work was supported by R01HL062300, R01HL077398, and R01HL115955. Mr. Greiner is  
22 also supported by an NIH Ruth L. Kirschstein F30 fellowship (F30HL143908) and by a T32 training grant  
23 held by the University of Iowa Medical Scientist Training Program (T32GM007337).

24  
25 Conflicts of Interest: The authors have nothing to disclose.

26  
27 Word count: 3379

28 Address for correspondence:

29 Barry London, M.D., Ph.D.

30 285 Newton Road

31 2283 Carver Biomedical Research Building

32 Iowa City, Iowa 52242

33 United States of America

34 Fax: 319-353-6343

35 Telephone: 319-356-2750

36 e-mail address: [barry-london@uiowa.edu](mailto:barry-london@uiowa.edu)

37

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 38 **Abstract**

### 39 **Background**

40 Brugada Syndrome (BrS) is an inherited arrhythmia syndrome in which mutations in *SCN5A* account for  
41 20% of cases. Mutations in other ion channels or channel-modifying genes may account for an additional  
42 10% of cases, though recent analysis has suggested that *SCN5A* should be regarded as the sole monogenic  
43 cause of BrS.

### 44 **Objective**

45 We sought to re-assess the genetic underpinnings of BrS in a large multigenerational family with a putative  
46 GPD1L-A280V mutation.

### 47 **Methods**

48 Fine linkage mapping was performed in the family using the Illumina Global Screening array. Whole exome  
49 sequencing of the proband was performed to identify rare variants and mutations, and Sanger sequencing  
50 was used to assay previously-reported risk single nucleotide polymorphisms (SNPs) for BrS.

### 51 **Results**

52 Linkage analysis decreased the size of the previously-reported microsatellite linkage region to ~3 megabases.  
53 GPD1L-A280V was the only rare coding non-synonymous variation present at <1% allele frequency in the  
54 proband within the linkage region. Other variants were either synonymous, or in genes not known to play a  
55 role in BrS and that failed to co-segregate with BrS in the large family. Risk SNPs known to predispose to  
56 BrS were overrepresented in affected members of the family.

### 57 **Conclusion**

58 Together, our linkage and sequencing data suggest GPD1L-A280V remains the most likely cause of BrS in  
59 this large multigenerational family. While care should be taken in interpreting variant pathogenicity given  
60 the genetic uncertainty of BrS, our data support inclusion of other putative BrS in clinical genetic panels.

61 **Keywords:** inherited, arrhythmia, genetics, exome sequencing, sudden death

62  
63 **Abbreviations:** BrS: Brugada Syndrome, SNP: Single nucleotide polymorphism, CM: centimorgan, LOD:  
64 logarithm of the odds, Mb: megabase, ICD: implantable cardioverter defibrillator, RBBB: right bundle  
65 branch block, VT: ventricular tachycardia

66

## 1 Introduction

Brugada Syndrome (BrS) is an inherited arrhythmia syndrome characterized by ST-segment elevation in the right precordial leads ( $V_1$  through  $V_3$ ) and sudden cardiac death.<sup>1</sup> The molecular mechanism underpinning BrS was initially described as autosomal-dominant loss-of-function mutations in the main cardiac sodium channel,  $Na_v1.5$ , encoded on chromosome 3 by *SCN5A*.<sup>2</sup> These loss-of-function mutations result in decreased inward depolarizing sodium current, which can result in premature repolarization of the epicardium in the right ventricle, slowed conduction, ventricular tachyarrhythmias and sudden cardiac death.<sup>3</sup> However, only around 20% of patients with Brugada Syndrome have mutations in *SCN5A*. The advent of massively parallel sequencing has allowed many groups to investigate the genetic underpinnings of BrS over the past two decades. These genetic data, in combination with molecular studies, have expanded the number of putative disease-causing genes in BrS from one gene, *SCN5A*, to over 20 genes today. Genes reported to have mutations which cause BrS can be broadly classified as those which encode 1) sodium channels, 2) potassium channels, 3) channel interacting proteins, and 4) metabolic proteins.<sup>4</sup> Recent reports have also suggested BrS may be polygenic in nature, with single nucleotide polymorphisms (SNPs) at the *SCN5A-SCN10A* and *HEY2* loci predisposing individuals to BrS.<sup>5</sup>

Our lab first reported a large, multigenerational family with BrS.<sup>6</sup> Initial linkage mapping using microsatellites identified an ~15 centimorgan (CM) region on chromosome 3 with a LOD score  $>4$  that did not contain *SCN5A* or *SCN10A*.<sup>7</sup> Positional cloning and subsequent molecular analysis identified a variant in glycerol 3-phosphate dehydrogenase 1-like (*GPD1L*) as the putative cause of this family's disease. Peak sodium current in HEK293 cells transfected with  $Na_v1.5$  decreased if cells were co-transfected with *GPD1L-A280V* compared to those co-transfected with *GPD1L-WT*. Additional studies suggested *GPD1L-A280V* decreases  $Na_v1.5$  membrane expression. Together, a decrease in peak sodium current and a decrease in membrane localization suggest that *GPD1L-A280V* is pathogenic for BrS.

The explosion of genetic data, especially variants of uncertain significance, from clinical genetic testing has led to a plethora of putative mutations but a dearth of scientific evidence supporting the pathogenicity of these variants. Concerns about variants of uncertain significance being classified as pathogenic without data to support the claim has been reviewed in many publications.<sup>8,9</sup> This concern sparked a review of the pathogenicity of reported BrS genes using the Clinical Genome Resources (ClinGen) framework. This review determined that *SCN5A* was the only gene with sufficient scientific evidence to definitively be regarded as a causative gene for BrS.<sup>10</sup> *GPD1L* was excluded due to a large linkage region in which other genes had not been sequenced and because the allele frequency of *GPD1L-A280V* was relatively high (gnomAD V2.1.1 allele frequency =  $1.29E-4$ ).<sup>11</sup>

In the present study, we provide high-depth whole exome sequencing data in the proband of our originally-reported large multigenerational family, SNP-based linkage analysis of affected individuals, and sequencing data of previously defined BrS risk SNPs to support our initial reports that *GPD1L-A280V* is pathogenic for BrS.

## 2 Methods

### 2.1 Patient enrollment and phenotype validation

Patients were enrolled under protocols approved through the University of Pittsburgh and University of Iowa Institutional Review Boards (IRBs). All individuals in the study provided informed consent for participation in the study. Type 1, Type 2, or Type 3 Brugada Syndrome, or clinically unaffected status, was determined

108 through clinical history, electrocardiogram analysis, and clinical provocative testing using procainamide as  
109 previously described.<sup>6</sup>

## 110 **2.2 Genomic DNA isolation and RNase A treatment**

111 Genomic DNA was isolated from peripheral blood using commercially-available kits or automated machine  
112 as previously described.<sup>6</sup> Isolated DNA was treated with RNase A and re-isolated by ethanol precipitation  
113 prior to sequencing. DNA integrity was assessed by agarose gel electrophoresis and quantified using Qubit  
114 High Sensitivity DNA assays (ThermoFisher Scientific).

## 115 **2.3 SNP calling and Linkage Analysis**

116 Ten affected and five unaffected individuals from the family had genomic DNA prepared as described above.  
117 After passing quality control and subsequent library preparation, SNPs were called using the Infinium Global  
118 Screening Array (Illumina) at CD Genomics (Shirley, NY, USA) which sequences approximately 654,027  
119 SNPs. Call rates were greater than 98% for all individuals. (Supplemental Table 1) Chromosomes were  
120 phased using ShapeIt2 with DuoHMM enabled and the reference HapMap Phase II data.<sup>12,13</sup> The resultant  
121 phased haplotypes were investigated manually for recombination using our previously-reported microstaelite  
122 data as the starting point. Logarithm of odds scores were calculated using Superlink-Online SNP.<sup>14</sup>

## 123 **2.4 High-depth whole exome sequencing and analysis**

124 Whole exome sequencing was performed at the Iowa Institute of Human Genetics (IIHG) on genomic DNA  
125 prepared as described above. Library preparation was performed using standard protocols for the Agilent  
126 SureSelect V6 + UTR library preparation kit (Agilent Technologies). The resulting 150 base pair paired-  
127 end library was sequenced on an Illumina HiSeq 4000. Resultant .fastq files underwent quality control using  
128 FastQC.<sup>15</sup> Alignment, variant calling, and variant annotation were performed using BWA-MEM (alignment),  
129 GATK4 (variant calling), and SnpEff (variant annotation) using an implementation of BCBio and the  
130 GRCh37 reference genome.<sup>16-21</sup> A second variant calling tool, FreeBayes, was used in a near-identical  
131 pipeline to ensure consensus variant calls were achieved<sup>22</sup>. Greater than 80% of targeted bases had greater  
132 than 50x coverage. (Supplemental Figure 1) A brief summary of sequencing results is shown in Supplemental  
133 Table 2.

134 Two approaches were used to identify candidate variants 1) a linkage-region focused analyses and 2)  
135 a linkage-naive approach. The linkage-region focused analysis was limited to the newly-defined linkage  
136 region on chromosome 3, while the linkage-naive approach entertained variants on any autosome. For  
137 both approaches, the resulting annotated variant call file was used to generate a database compatible with  
138 Gemini.<sup>23</sup> Variants present at less than 1% minor allele frequency, a lenient threshold for autosomal dominant  
139 disease, were included. Variants were then segregated according to impact (nonsense, splicing, missense,  
140 synonymous) with synonymous variants removed from consideration. Variant location information, either  
141 exonic, UTR, intronic, or intergenic, was subsequently used in prioritization of variants.

## 142 **2.5 Sanger Sequencing of Risk SNPs**

143 Sanger sequencing of BrS risk SNPs was performed at the Iowa Institute of Human Genetics using custom  
144 primers designed in-lab and synthesized by Integrated DNA Technologies. (Supplemental Table 3) The  
145 resulting chromatograms were analyzed using NCBI Blast, Finch, and SnapGene from which wild-type,  
146 heterozygous, or homozygous SNP calls were made and manually validated.

## 147 **2.6 Protein and variant modeling**

148 A single unpublished protein model of GPD1L is present on the RCSB Protein Databank.<sup>23,24</sup> AlphaFold  
149 computational models for GPD1L are also publicly available from EMBL. The AlphaFold GPD1L model AF-  
150 Q8N335-F1-model\_v1 was downloaded and imported into PyMol.<sup>25</sup> The mutagenesis function of PyMol was  
151 used to visualize the impact of the three predicted GPD1L-A280V rotamers. Strain scores were calculated  
152 for all rotamers within PyMol. (Supplemental Figure 2) Variant data for *GPD1L* was downloaded from  
153 ClinVar.<sup>26</sup>

## 154 **3 Results**

### 155 **3.1 Linkage analysis reaffirms a region on chromosome 3 co-segregates with** 156 **Brugada Syndrome**

157 To understand the linked genomic regions within this family we performed linkage analysis using the Illumina  
158 Global Screening Array with ten affected and five unaffected family members. The previously-identified 15  
159 CM linkage region in this family which we reported was used as a starting point for our investigation.<sup>6</sup>  
160 Analysis of phased haplotypes identified a narrowed linkage region defined by the SNPs rs13059657 and  
161 rs7651953 (GRCh37, chr3:29,899,567-32,970,737). (Figure 1) Individuals III-2 and III-8 defined the 5' and  
162 3' breakpoints, respectively. Calculation of LOD scores using individuals having a Type 1 EKG pattern or  
163 positive procainamide test, in addition to I-I and I-II from Figure 1, using Superlink-Online SNP results in  
164 a LOD score of 2.02 for this region.<sup>14</sup> The addition of individuals with Type II EKG patterns results in a  
165 LOD score of 3.18. The region of interest contains 14 genes, including *GPD1L*, but not *SCN5A* or *SCN10A*  
166 which are approximately 6 Mb downstream. (Figure 1)

### 167 **3.2 Whole-exome sequencing analysis affirms GPD1L-A280V as the only rare** 168 **exonic variant in the linked region**

169 High-depth (100x) whole exome sequencing of the proband was performed using the Agilent SureSelect  
170 V6+UTR capture kit. Limiting the analysis to the newly defined linkage region identified GPD1L-A280V  
171 as the only rare, exonic coding variation. No other exonic or splice variants occurred at an allele fre-  
172 quency of less than 1%. The proband carried missense variants in arrhythmia and cardiomyopathy genes  
173 not usually associated with BrS: one missense variant in ANK2 (p.R2416G;c.7246C>G, unreported), one  
174 in FHL2 (p.V187M;c.559G>A, f= 6.78E-5) and two in TTN (p.A31503T;c94507G>A, f= 5.04E-5 and  
175 p.F14410C;c.43229T>G, unreported) (Table 1). Linkage analysis and Sanger sequencing showed that none  
176 of these variants cosegregate with BrS in this family, and no other variants are annotated as pathogenic for  
177 cardiovascular diseases in the ClinVar database.

### 178 **3.3 The SCN5A and SCN10A BrS risk SNPs are linked to GPD1L-A280V in** 179 **this family**

180 Three published risk SNPs for BrS [rs10428132 (*SCN10A*; total minor allele frequency, dbSNP (MAF) =  
181 0.40), rs11708996 (*SCN5A*; MAF=0.14), and rs9388451 (*HEY2*; MAF=0.42)] identified by Bezzina et al.  
182 were assessed in family members with sufficient DNA, showing 8/15 affected subjects (those demonstrating a  
183 Type I, II, or III BrS pattern) in generations II and III are homozygous for the SCN10A risk allele and 12/15  
184 subjects are heterozygous for the SCN5A risk allele (Figure 1). *SCN5A* and *SCN10A* are near *GPD1L* on

185 chromosome 3; in most affected individuals the GPD1L-A280V mutation co-segregated with one SCN5A and  
186 one SCN10A risk allele. The HEY2 risk SNP on chromosome 6 segregated in Mendelian fashion. Overall,  
187 individuals affected with BrS (n=15) carried  $3.3 \pm 0.2$  risk SNPs, while unaffected individuals (n=12) carried  
188  $2.1 \pm 0.4$  risk SNPs (p=0.012). (Figure 2) The SCN5A and SCN10A risk SNPs carried along with GPD1L-  
189 A280V in this family may potentiate the pathogenicity of GPD1L-A280V.

### 190 **3.4 GPD1L-A280V may introduce protein instability in computationally-predicted** 191 **models**

192 *In silico* mutagenesis of the A280 residue to V280 in the computational model of GPD1L demonstrates  
193 increased strain within the alpha helix in which residue 280 resides. (Figure 3 and Supplemental Figure 2)  
194 Thus, *in silico* mutagenesis results in increased computationally-predicted strain stores indicating GPD1L-  
195 A280V may introduce steric hinderance in the GPD1L tertiary structure.

## 196 **4 Discussion**

### 197 **4.1 The genetic architecture of BrS in one large, multigenerational family**

198 Our analysis of this large, multigenerational family narrows the linkage region to approximately 3.1 megabases  
199 which includes *GPD1L* but excludes *SCN5A* and *SCN10A*. Whole exome sequencing confirmed GPD1L-  
200 A280V as the only rare exonic variant at an allele frequency <1% within this region. The affected-only  
201 LOD score of 3.18 for individuals displaying Type I and Type II BrS patterns (Type 1 BrS alone = 2.02),  
202 suggests this region is linked to BrS in this family and is consistent with the previous reported LOD score of  
203 >3 which included unaffected individuals. While not proving pathogenicity of the GPD1L-A280V mutation,  
204 these data, along with previously published experiment data should be considered when assessing the role  
205 of GPD1L in the pathogenesis of BrS.

206 While the allele frequency of GPD1L-A280V is high relative to published allele frequency cutoffs, GPD1L-  
207 A280V is not the lone reported *GPD1L* putative mutation.<sup>27</sup> Four other putative mutations, p.I124V,  
208 p.E174K, p.R231C, and p.Q345H, have been reported in ClinVar. (Figure 4)<sup>28</sup> Nevertheless, we believe  
209 that mutations in GPD1L, in isolation, are likely unable to cause sufficient decreases in sodium current to  
210 precipitate BrS. It is likely that GPD1L mutations and risk polymorphisms act in concert to precipitate  
211 BrS, as is the case of this large multigenerational family. We believe that SCN5A is the only gene in which  
212 mutations are sufficient to cause enough inward sodium current decrease to cause BrS, while GPD1L—and  
213 possibly other reported BrS genes—precipitate BrS in a polygenic manner or alongside risk SNPs.

### 214 **4.2 The genetic architecture of BrS: past, present, and future**

215 Mutations in *SCN5A* are certainly the predominant genetically-identifiable cause of BrS.<sup>1</sup> Future studies of  
216 *GPD1L* and other putative BrS mutations in heterologous systems and in mouse models will continue provide  
217 information on the role these genes play in cardiac physiology. Surprisingly, few reports exist of the use of  
218 whole-exome or whole-genome sequencing to identify the genetic underpinnings of BrS, and the majority of  
219 these studies identify genetic variation in previously reported disease genes. Future large genomic datasets  
220 (e.g. UK Biobank, gnomAD) have and will continue to provide further information on allele frequency of  
221 genes reported to cause BrS. In all, these data and future studies will further our understanding of the still  
222 uncertain genetic architecture of BrS.

### 223 4.3 Study limitations

224 Our study uses linkage and exome sequencing data from a single family or single proband. Linkage data  
225 provide an incomplete picture of the genetic architecture for a disease, though we believe the addition of  
226 exome sequencing partly addresses this limitation. Notably, exome sequencing libraries are not targeted to  
227 capture intronic sequences. Deep intronic variants within *GPD1L* may contribute to disease in this family.

### 228 4.4 Clinical implications

229 Recent recommendations to clinical genetic testing panels exclude all genes except *SCN5A* in their testing  
230 panels. While well-intentioned to avoid undue harm from provider misinterpretation, this may reduce iden-  
231 tification of rare variation contributing to BrS in sodium channel modifying genes, among others. While  
232 concerns for generating undue harm from misinterpretation of a variant of uncertain significance in a disputed  
233 gene included on a clinical genetic testing panel are valid, we believe these concerns highlight the necessity  
234 of thorough understanding of genetic testing results and the importance both of cardiologists trained in  
235 genetics and the use of genetic counselors.<sup>29,30</sup>

236 Our study demonstrates that mutation in *GPD1L* likely contributes to BrS in this multigenerational  
237 family. Given this, inclusion of *GDP1L* on genetic testing panels should be reconsidered.

## 238 5 Conclusion

239 We identified *GPD1L*-A280V as the only rare non-synonymous coding variation in the refined linkage region  
240 in a large, multigenerational family. Associated BrS risk SNPs may be permissive for the BrS phenotype in  
241 affected family members. In addition, the A280V mutation may alter the *GPD1L* tertiary structure. While  
242 mutation in *SCN5A* is the most common genetically-identified cause of BrS, our study suggests that  
243 *GPD1L* should still be considered when evaluating the genetic underpinnings of BrS.



244

## 245 References

- 246 [1] J Brugada, P Brugada, and R Brugada. “The Syndrome of Right Bundle Branch Block ST Segment  
247 Elevation in V1 to V3 and Sudden Death—the Brugada Syndrome.” In: *Europace : European pacing,  
248 arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhyth-  
249 mias, and cardiac cellular electrophysiology of the European Society of Cardiology* 1.3 (1999), pp. 156–  
250 66. DOI: 10.1053/eupc.1999.0033. pmid: 11225790.
- 251 [2] Qiuyun Chen et al. “Genetic Basis and Molecular Mechanism for Idiopathic Ventricular Fibrillation”.  
252 In: *Nature* 392.6673 (6673 Mar. 1998), pp. 293–296. DOI: 10.1038/32675.
- 253 [3] Charles Antzelevitch et al. “Brugada Syndrome: 1992–2002”. In: *Journal of the American College of  
254 Cardiology* 41.10 (2003).
- 255 [4] Josep Brugada et al. “Present Status of Brugada Syndrome: JACC State-of-the-Art Review”. In:  
256 *Journal of the American College of Cardiology* 72.9 (Aug. 28, 2018), pp. 1046–1059. DOI: 10.1016/j.  
257 jacc.2018.06.037. pmid: 30139433.
- 258 [5] Connie R Bezzina et al. “Common Variants at SCN5A-SCN10A and HEY2 Are Associated with  
259 Brugada Syndrome, a Rare Disease with High Risk of Sudden Cardiac Death”. In: *Nature Genetics*  
260 45.9 (Sept. 21, 2013), pp. 1044–1049. DOI: 10.1038/ng.2712. pmid: 23872634.
- 261 [6] Barry London et al. “Mutation in Glycerol-3-Phosphate Dehydrogenase 1 like Gene (GPD1-L) De-  
262 creases Cardiac Na<sup>+</sup> Current and Causes Inherited Arrhythmias.” In: *Circulation* 116.20 (Nov. 13,  
263 2007), pp. 2260–8. DOI: 10.1161/CIRCULATIONAHA.107.703330. pmid: 17967977.
- 264 [7] Raul Weiss et al. “Clinical and Molecular Heterogeneity in the Brugada Syndrome”. In: *Circulation*  
265 105.6 (Feb. 12, 2002), pp. 707–713. DOI: 10.1161/hc0602.103618.
- 266 [8] Michael J. Ackerman. “Genetic Purgatory and the Cardiac Channelopathies: Exposing the Variants of  
267 Uncertain/Unknown Significance Issue”. In: *Heart Rhythm* 12.11 (Nov. 1, 2015), pp. 2325–2331. DOI:  
268 10.1016/j.hrthm.2015.07.002. pmid: 26144349.
- 269 [9] Jamie D. Kapplinger et al. “Enhanced Classification of Brugada Syndrome–Associated and Long-QT  
270 Syndrome–Associated Genetic Variants in the *SCN5A* -Encoded Na<sup>v</sup> 1.5 Cardiac Sodium Channel”.  
271 In: *Circulation: Cardiovascular Genetics* 8.4 (Aug. 2015), pp. 582–595. DOI: 10.1161/CIRCGENETICS.  
272 114.000831. pmid: 25904541.
- 273 [10] S. Mohsen Hosseini et al. “Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-  
274 based Evaluation of Gene Validity for Brugada Syndrome”. In: *Circulation* 138.12 (June 29, 2018),  
275 pp. 1195–1205. DOI: 10.1161/CIRCULATIONAHA.118.035070. pmid: 29959160.
- 276 [11] Konrad J. Karczewski et al. “The Mutational Constraint Spectrum Quantified from Variation in  
277 141,456 Humans”. In: *Nature* 581.7809 (May 28, 2020), pp. 434–443. DOI: 10.1038/s41586-020-  
278 2308-7. pmid: 32461654.
- 279 [12] Olivier Delaneau, Jean-Francois Zagury, and Jonathan Marchini. “Improved Whole-Chromosome Phas-  
280 ing for Disease and Population Genetic Studies”. In: *Nat Methods* 10.1 (1 Jan. 2013), pp. 5–6. DOI:  
281 10.1038/nmeth.2307.
- 282 [13] “A Second Generation Human Haplotype Map of over 3.1 Million SNPs”. In: *Nature* 449.7164 (Oct. 18,  
283 2007), pp. 851–861. DOI: 10.1038/nature06258. pmid: 17943122.




- 284 [14] M. Silberstein et al. “A System for Exact and Approximate Genetic Linkage Analysis of SNP Data in  
285 Large Pedigrees”. In: *Bioinformatics* 29.2 (Jan. 15, 2013), pp. 197–205. DOI: 10.1093/bioinformatics/  
286 bts658. pmid: 23162081.
- 287 [15] S Andrews. *FastQC: A Quality Control Tool for High Throughput Sequence Data*. URL: [http://www.  
288 bioinformatics.babraham.ac.uk/projects/fastqc](http://www.bioinformatics.babraham.ac.uk/projects/fastqc).
- 289 [16] Heng Li. *Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM*. May 26,  
290 2013. arXiv: 1303.3997 [q-bio]. URL: <http://arxiv.org/abs/1303.3997> (visited on 11/22/2021).
- 291 [17] Mark A DePristo et al. “A Framework for Variation Discovery and Genotyping Using Next-Generation  
292 DNA Sequencing Data”. In: *Nature Genetics* 43.5 (May 10, 2011), pp. 491–498. DOI: 10.1038/ng.806.
- 293 [18] Ryan Poplin et al. “Scaling Accurate Genetic Variant Discovery to Tens of Thousands of Samples”.  
294 In: *bioRxiv* (July 24, 2018), p. 201178. DOI: 10.1101/201178.
- 295 [19] Pablo Cingolani et al. “A Program for Annotating and Predicting the Effects of Single Nucleotide  
296 Polymorphisms, SnpEff: SNPs in the Genome of *Drosophila Melanogaster* Strain W1118; Iso-2; Iso-3”.  
297 In: *Fly (Austin)* 6.2 (2012 Apr-Jun), pp. 80–92. DOI: 10.4161/fly.19695. pmid: 22728672.
- 298 [20] Brad Chapman et al. *Bcbio/Bcbio-Nextgen*. Zenodo, Apr. 14, 2021. DOI: 10.5281/zenodo.4686097.
- 299 [21] Deanna M. Church et al. “Modernizing Reference Genome Assemblies”. In: *PLoS Biol* 9.7 (July 2011),  
300 e1001091. DOI: 10.1371/journal.pbio.1001091. pmid: 21750661.
- 301 [22] Erik Garrison and Mark Marth. “Haplotype-Based Variant Detection from Short-Read Sequencing  
302 Erik Garrison and Gabor Marth January 12, 2016 Abstract”. In: (2016), pp. 1–20. DOI: 10.1093/  
303 bioinformatics/btv440. pmid: 24136966.
- 304 [23] Umadevi Paila et al. “GEMINI: Integrative Exploration of Genetic Variation and Genome Annota-  
305 tions.” In: *PLoS computational biology* 9.7 (2013), e1003153. DOI: 10.1371/journal.pcbi.1003153.  
306 pmid: 23874191.
- 307 [24] RCSB Protein Data Bank. *RCSB PDB - 2PLA: Crystal Structure of Human Glycerol-3-Phosphate  
308 Dehydrogenase 1-like Protein*. URL: <https://www.rcsb.org/structure/2PLA> (visited on 11/22/2021).
- 309 [25] John Jumper et al. “Highly Accurate Protein Structure Prediction with AlphaFold”. In: *Nature*  
310 596.7873 (7873 Aug. 2021), pp. 583–589. DOI: 10.1038/s41586-021-03819-2.
- 311 [26] Melissa J. Landrum et al. “ClinVar: Improving Access to Variant Interpretations and Supporting  
312 Evidence”. In: *Nucleic Acids Res* 46.D1 (Jan. 4, 2018), pp. D1062–D1067. DOI: 10.1093/nar/gkx1153.  
313 pmid: 29165669.
- 314 [27] Nicola Whiffin et al. “Using High-Resolution Variant Frequencies to Empower Clinical Genome Inter-  
315 pretation”. In: *Genetics in Medicine* 19.10 (Oct. 18, 2017), pp. 1151–1158. DOI: 10.1038/gim.2017.26.  
316 pmid: 28518168.
- 317 [28] David W. Van Norstrand et al. “Molecular and Functional Characterization of Novel Glycerol-3-  
318 Phosphate Dehydrogenase 1 like Gene (GPD1-L) Mutations in Sudden Infant Death Syndrome”. In:  
319 *Circulation* 116.20 (Nov. 13, 2007), pp. 2253–2259. DOI: 10.1161/CIRCULATIONAHA.107.704627. pmid:  
320 17967976.
- 321 [29] Ferhaan Ahmad et al. “Establishment of Specialized Clinical Cardiovascular Genetics Programs: Rec-  
322 ognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Associ-  
323 ation”. In: *Circulation: Genomic and Precision Medicine* 12.6 (June 2019), e000054. DOI: 10.1161/  
324 HCG.0000000000000054. pmid: 31117808.

- 325 [30] Eric D. Green et al. “Strategic Vision for Improving Human Health at The Forefront of Genomics”.  
326 In: *Nature* 586.7831 (7831 Oct. 2020), pp. 683–692. DOI: 10.1038/s41586-020-2817-4.

327 **Figures and Tables**

328 **Figure 1:**



329


330 **Figure legend:**

331 **Title:** Representative pedigree of the family, linkage analysis, and assessment of Brugada Syndrome (BrS)  
332 risk SNPs.


333 **Caption:** A) Linkage analysis demonstrates a small region on chromosome 3 (inset map and green bracketed region) which has undergone recombination in the third generation of the pedigree. Previously reported  
334 eted region) which has undergone recombination in the third generation of the pedigree. Previously reported  
335 risk SNPs (SCN5A and SCN10A, red) for the BrS phenotype are associated with the GPD1L-A280V. B)  
336 The 3 megabase region on chromosome 3 identified by linkage analysis contains 14 genes, including *GPD1L*.  
337 *SCN5A* and *SCN10A* lie upstream of *GPD1L* (ideogram, red text) and outside of the refined linkage region  
338 (ideogram, red box). ICD: implantable cardioverter defibrillator. +Proc: positive procainamide challenge.  
339 RBBB: right bundle branch block. VT: ventricular tachycardia.

340

341 Figure 2:



349 Figure 3:



350

351 Figure legend:


352 **Title:** Computational modeling of GPD1L suggests A280V introduces steric clashing

353 **Caption:**

354 Left: The wild-type GPD1L structure as calculated by AlphaFold (AF-Q8N335-F1-model\_v1) with residue  
355 A280 highlighted in blue. A280 resides in an alpha helix. Right: One of three putative GPD1L-A280V  
356 rotamers as calculated by PyMol. All three predicted rotamers introduce strain in the alpha helix.

357

358 Figure 4:



360 Figure legend:

361 **Title:** Reported GPD1L variants in ClinVar show GPD1L-A280V is not the sole reported putative mutation.

362 **Caption:** Missense variants with conflicting interpretation (yellow circles, with GPD1L-A280V highlighted  
363 as red) and variants of uncertain significance (black bars, 83 total) were downloaded from ClinVar (accessed  
364 November 12, 2021) and plotted along the full length of GPD1L. All five variants with conflicting interpre-  
365 tation, including GPD1L-A280V, were submitted to ClinVar by their respective submitters with Brugada  
366 Syndrome as the clinical condition.

367

**Table 1.** Variants in reported Brugada Syndrome or Inherited Cardiac Condition (ICC) List Genes

<b>Gene List</b>	<b>Position</b>	<b>Consequence</b>	<b>Gene</b>	<b>Frequency</b>
<b>Linkage region</b>	chr3:32200588C>T	p.Ala280Val	GPD1L	1.29E-04
<b>BrS</b>	chr12:2788732C>T	p.Gly1738Gly	CACNA1C	1.21E-05
	chr2:105979871C>T	p.Val187Met	FHL2	6.78E-05
	chr2:179411745C>T	p.Ala31503Thr	TTN	5.04E-05
<b>ICC</b>	chr2:179497504A>C	p.Phe14410Cys	TTN	Unreported
	chr4:114277020C>G	p.Arg2416Gly	ANK2	Unreported
	chr16:15844004G>A	p.His690His	MYH11	5.25E-04